Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the murine neutropenic thigh model

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 4, 2018, Pages

  Kang, Anthony D ^a,c   Smith, Kenneth P ^a   Berg, Anders H ^a   Truelson, Katherine A ^a,b   Eliopoulos, George M ^a   McCoy, Christopher ^a   Kirby, James E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY   (United States)

^c U S ARMY   (United States)

Author keywords

Antimicrobial; Apramycin; Maximum tolerated dose; Mouse thigh model; Pharmacodynamics; Pharmacokinetics; Resistance; Time kill

Indexed keywords

APRAMYCIN; ANTIINFECTIVE AGENT; NEBRAMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COLONY FORMING UNIT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; MAXIMUM CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THIGH; ANALOGS AND DERIVATIVES; ANIMAL; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY;

ACINETOBACTER BAUMANNII; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICE; MICROBIAL SENSITIVITY TESTS; NEBRAMYCIN; THIGH;

EID: 85044505646     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02585-17     Document Type: Article

References (30)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. https://doi.org/10.1086/595011.
2. Perzynski S, Cannon M, Cundliffe E, Chahwala SB, Davies J. 1979. Effects of apramycin, a novel aminoglycoside antibiotic on bacterial protein synthesis. Eur J Biochem 99:623-628. https://doi.org/10.1111/j.1432-1033.1979.tb13295.x.
3. Matt T, Ng CL, Lang K, Sha SH, Akbergenov R, Shcherbakov D, Meyer M, Duscha S, Xie J, Dubbaka SR, Perez-Fernandez D, Vasella A, Ramakrishnan V, Schacht J, Bottger EC. 2012. Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci U S A 109:10984-10989. https://doi.org/10.1073/pnas.1204073109.
4. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. 1984. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100:352-357. https://doi.org/10.7326/0003-4819-100-3-352.
5. Humes HD. 1988. Aminoglycoside nephrotoxicity. Kidney Int 33: 900-911. https://doi.org/10.1038/ki.1988.83.
6. Kang AD, Smith KP, Eliopoulos GM, Berg AH, McCoy C, Kirby JE. 2017. In vitro apramycin activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 88: 188-191. https://doi.org/10.1016/j.diagmicrobio.2017.03.006.
7. Smith KP, Kirby JE. 2016. Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae. Diagn Microbiol Infect Dis 86:439-441. https://doi.org/10.1016/j.diagmicrobio.2016.09.002.
8. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66:48-53. https://doi.org/10.1093/jac/dkq408.
9. Hu Y, Liu L, Zhang X, Feng Y, Zong Z. 2017. In vitro activity of neomycin, streptomycin, paromomycin and apramycin against carbapenemresistant Enterobacteriaceae clinical strains. Front Microbiol 8:2275. https://doi.org/10.3389/fmicb.2017.02275.
10. Liu Z, Ling B, Zhou L. 2015. Prevalence of 16S rRNA methylase, modifying enzyme, and extended-spectrum beta-lactamase genes among Acinetobacter baumannii isolates. J Chemother 27:207-212. https://doi.org/10.1179/1973947814Y.0000000190.
11. Tada T, Tsuchiya M, Shimada K, Nga TTT, Thu LTA, Phu TT, Ohmagari N, Kirikae T. 2017. Dissemination of carbapenem-resistant Klebsiella pneumoniae clinical isolates with various combinations of carbapenemases (KPC-2, NDM-1, NDM-4, and OXA-48) and 16S rRNA methylases (RmtB and RmtC) in Vietnam. BMC Infect Dis 17:467. https://doi.org/10.1186/s12879-017-2570-y.
12. Poirel L, Schrenzel J, Cherkaoui A, Bernabeu S, Renzi G, Nordmann P. 2011. Molecular analysis of NDM-1-producing enterobacterial isolates from Geneva, Switzerland. J Antimicrob Chemother 66:1730-1733. https://doi.org/10.1093/jac/dkr174.
13. Seiffert SN, Marschall J, Perreten V, Carattoli A, Furrer H, Endimiani A. 2014. Emergence of Klebsiella pneumoniae co-producing NDM-1, OXA- 48, CTX-M-15, CMY-16, QnrA and ArmA in Switzerland. Int J Antimicrob Agents 44:260-262. https://doi.org/10.1016/j.ijantimicag.2014.05.008.
14. Galani I, Anagnostoulis G, Chatzikonstantinou M, Petrikkos G, Souli M. 2016. Emergence of Klebsiella pneumoniae co-producing OXA-48, CTXM- 15, and ArmA in Greece. Clin Microbiol Infect 22:898-899. https://doi.org/10.1016/j.cmi.2016.08.002.
15. Dortet L, Poirel L, Al Yaqoubi F, Nordmann P. 2012. NDM-1, OXA-48 and OXA-181 carbapenemase-producing Enterobacteriaceae in Sultanate of Oman. Clin Microbiol Infect 18:E144-E148. https://doi.org/10.1111/j.1469-0691.2012.03796.x.
16. Landman D, Kelly P, Bäcker M, Babu E, Shah N, Bratu S, Quale J. 2011. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 66:332-334. https://doi.org/10.1093/jac/dkq459.
17. Yu Y-s, Zhou H, Yang Q, Chen Y-g, Li L-j. 2007. Widespread occurrence of aminoglycoside resistance due to ArmA methylase in imipenemresistant Acinetobacter baumannii isolates in China. J Antimicrob Chemother 60:454-455. https://doi.org/10.1093/jac/dkm208.
18. Wachino J, Shibayama K, Kurokawa H, Kimura K, Yamane K, Suzuki S, Shibata N, Ike Y, Arakawa Y. 2007. Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob Agents Chemother 51:4401-4409. https://doi.org/10.1128/AAC.00926-07.
19. Lioy VS, Goussard S, Guerineau V, Yoon E-J, Courvalin P, Galimand M, Grillot-Courvalin C. 2014. Aminoglycoside resistance 16S rRNA methyltransferases block endogenous methylation, affect translation efficiency and fitness of the host. RNA 20:382-391. https://doi.org/10.1261/rna.042572.113.
20. Clinical and Laboratory Standards Institute. 1999. Methods for determining the bactericidal activity of antimicrobial agents; approved guideline. CLSI document M-26A. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Herigstad B, Hamilton M, Heersink J. 2001. How to optimize the drop plate method for enumerating bacteria. J Microbiol Methods 44: 121-129. https://doi.org/10.1016/S0167-7012(00)00241-4.
22. Craig WA, Redington J, Ebert SC. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27(Suppl C):29-40. https://doi.org/10.1093/jac/27.suppl-C.29.
23. Bernardi PM, Barreto F, Dalla Costa T. 2017. Application of a LC-MS/MS method for evaluating lung penetration of tobramycin in rats by microdialysis. J Pharm Biomed Anal 134:340-345. https://doi.org/10.1016/j.jpba.2016.10.023.
24. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45:753-760. https://doi.org/10.1086/520991.
25. Moore RD, Smith CR, Lietman PS. 1984. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 149:443-448. https://doi.org/10.1093/infdis/149.3.443.
26. Meyer M, Freihofer P, Scherman M, Teague J, Lenaerts A, Bottger EC. 2014. In vivo efficacy of apramycin in murine infection models. Antimicrob Agents Chemother 58:6938-6941. https://doi.org/10.1128/AAC.03239-14.
27. Suzuki S, Takamura S, Yoshida J, Shinzawa Y, Niwa O, Tamatani R. 1995. Comparison of gentamicin nephrotoxicity between rats and mice. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 112:15-28. https://doi.org/10.1016/0742-8413(95)00075-5.
28. Schmitz C, Hilpert J, Jacobsen C, Boensch C, Christensen EI, Luft FC, Willnow TE. 2002. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 277:618-622. https://doi.org/10.1074/jbc.M109959200.
29. Suzuki S, Hatashima S, Shinzawa Y, Niwa O, Tamatani R. 1994. Toxicity of neomycin on enzyme activities of kidney and duodenal mucosa in vivo: organ specificity and species difference between rats and mice. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 109:77-92. https://doi.org/10.1016/0742-8413(94)00037-B.
30. Rodríguez Salgueiro S, González Núñez L. 2016. Animal models mimicking aminoglycoside-induced renal damage. J Nephropharmacol 5:1-3.